Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1979 2
1980 12
1981 7
1982 8
1983 13
1984 15
1985 14
1986 17
1987 21
1988 23
1989 37
1990 30
1991 42
1992 39
1993 39
1994 46
1995 49
1996 68
1997 96
1998 127
1999 103
2000 133
2001 140
2002 181
2003 221
2004 279
2005 370
2006 439
2007 487
2008 574
2009 680
2010 793
2011 953
2012 1210
2013 1411
2014 1692
2015 1925
2016 2087
2017 2362
2018 2790
2019 3329
2020 4072
2021 4947
2022 5782
2023 5631
2024 6305
2025 6876
2026 104

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50,824 results

Results by year

Filters applied: . Clear all
Page 1
Entanglement-enhanced nanoscale single-spin sensing.
Zhou X, Wang M, Ye X, Sun H, Guo Y, Han S, Chai Z, Ji W, Xia K, Shi F, Wang Y, Du J. Zhou X, et al. Among authors: guo y. Nature. 2025 Nov;647(8091):883-888. doi: 10.1038/s41586-025-09790-6. Epub 2025 Nov 26. Nature. 2025. PMID: 41299049
[Cuprotosis and cardiovascular diseases].
Zhang TT, Wang ZL, Wang XX, Guo YF. Zhang TT, et al. Among authors: guo yf. Zhonghua Xin Xue Guan Bing Za Zhi. 2025 Nov 24;53(11):1294-1299. doi: 10.3760/cma.j.cn112148-20250924-00674. Zhonghua Xin Xue Guan Bing Za Zhi. 2025. PMID: 41287302 Review. Chinese.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.
Qin S, Gu S, Chan SL, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Xu L, Yuan X, Li D, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Du J, Shi W, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: guo y. Lancet Oncol. 2025 Dec;26(12):1598-1611. doi: 10.1016/S1470-2045(25)00543-1. Lancet Oncol. 2025. PMID: 41308676 Clinical Trial.
Role of Trace Elements in Antimicrobial Resistance Dynamics.
Chu J, Chen Y, Farhan MHR, Guo Y, Sui Y, Wang B, Yang X, Li Y, Cheng G. Chu J, et al. Among authors: guo y. Biotechnol Bioeng. 2025 Dec 2. doi: 10.1002/bit.70108. Online ahead of print. Biotechnol Bioeng. 2025. PMID: 41331974 Review.
Celastrol as a neuroprotective drug: current status and challenges.
Wang X, Li W, Liu X, Liang J, Wang L, Liu G, Liu Y, Song M, Li Z, Guo Y, Li S, Fu N, Zhang B. Wang X, et al. Among authors: guo y. Int Immunopharmacol. 2025 Nov 18;168(Pt 2):115846. doi: 10.1016/j.intimp.2025.115846. Online ahead of print. Int Immunopharmacol. 2025. PMID: 41260167 Review.
50,824 results
You have reached the last available page of results. Please see the User Guide for more information.